On Monday July 6th, the nanoHUB will be intermittently unavailable due to scheduled maintenance. We apologize for any inconvenience this may cause. close


Support Options

Submit a Support Ticket


Events: Details

Cancer Drug Research & Development Conference  edit    delete

Category: conference/workshop
Description: ear Colleague,

We invite you to join us at GTC's Inaugural Cancer Drug Research & Development Conference on May 6-7, 2014 in Berlin, Germany.

The Cancer Drug Research and Development Conference will bring together experts in industry and academia to discuss various approaches to the development of drugs as well as other promising therapeutics on the horizon. This conference will cover topics such as cancer targets, kinase inhibitors, drug resistance, combination therapy, cancer metabolism, invasion and metastasis, epigenetic regulators and immunotherapy.

Sessions for 2014 Agenda:
I. Drug Programs, Cancer Targets & Kinase Inhibitors
II. Drug Resistance & Combination Therapy
III. The Development of Drugs Targeting Metabolic Pathways
IV. Epigenetic Regulators as Drug Targets in Cancer
V. Invasion & Metastasis
VI. Cancer Immunotherapy & Checkpoint Inhibitors

This conference is part of our Europe Drug Discovery Summit, which will also feature three additional meetings over the course four days:

Europe Drug Discovery Summit:
Cancer Drug Research & Development (May 6-7, 2014)
Tissue Models & Drug Screening (May 6-7, 2014)
Drug Design & Medicinal Chemistry (May 8-9, 2014)
Protein Kinases in Drug Discovery (May 8-9, 2014)

We encourage you to sign up for a summit pass to have access to all four conferences.
When: Tuesday 06 May, 2014 2:00 pm CEST - Wednesday 07 May, 2014 8:00 pm CEST
Where: Berlin
Website: http://www.gtcbio.com/conference/cancer-drug-research-development-overview
  1. Cancer Drug
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

nanoHUB.org, a resource for nanoscience and nanotechnology, is supported by the National Science Foundation and other funding agencies. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.